Endogenous TCRs on the infused TILs recognize the tumor antigen peptide presented on HLA class II, triggering cytotoxic effector functions (perforin/granzyme release and Fas–FasL/TNF signaling) that induce apoptosis of peptide–HLA-II–positive cells.